Heart-valve manufacturer Edwards Lifesciences ( EW) said its second-quarter earnings jumped, helped by strong operating performance and sales growth from critical care and vascular products.

The Irvine, Calif.-based company earned $36.1 million, or 58 cents a share, in the quarter, compared with $13.9 million, or 22 cents a share, a year ago. Adjusted for items, earnings were 59 cents a share in the most recent quarter. Analysts polled by Thomson First Call were expecting earnings of 50 cents a share in the most recent quarter.

Second-quarter revenue rose 3.5% to $267.3 million, though hurt by foreign exchange and sales from discontinued businesses, as against analysts' expectation of $266.45 million.

The company expects to earn 45 cents to 47 cents a share in the third quarter, including 5 cents a share of options expenses. For the full year, the company raised its guidance earnings of $2.21 a share to $2.27 a share, excluding special items and 21 cents a share of options expenses, on revenue of $1.04 billion to $1.06 billion. Analysts are expecting earnings of 47 cents a share for the third quarter and $2.0 a share for the full year on revenue of $1.052 billion.

Gross profit rose 7% to $171.6 million while gross profit margin rose 210 basis points to 64.2% owing to a favorable foreign exchange impact and last year's divestiture of the low margin perfusion product line in Japan.

Sales in heart valve therapy increased 1.7% to $127.8 million and in critical care segment they increased 9.8% to $89.6 million. Cardiac surgery systems sales decreased 7.3% to $24.3 million and vascular's sales increased 13% to $19.1 million.

The company acquired about 1.3 million shares of its common stock for $56 million.

"During the quarter, we made good progress on all of our strategic growth initiatives, most notably in our percutaneous and Ascendra heart valve programs." the company said.

This story was created through a joint venture between TheStreet.com and IRIS.